Evidence base — read this first
Part of a family of short synthetic peptides (2-4 amino acids) developed by Vladimir Khavinson's research group, each targeted at a specific tissue/organ. The evidence base for this entire peptide family shares the same limitation: it's concentrated almost entirely within this one research lineage (largely the same institute, often the same handful of authors), is mostly preclinical (rodent, cell-culture) or small Russian human pilot work, and hasn't been independently replicated by unaffiliated Western labs in a way this research pass could verify. None of these compounds is FDA or EMA approved for human use anywhere.
Benefits
Bronchogen (Glu-Asp-Gly) is pitched as a lung/bronchial-tissue peptide, studied within the Khavinson bioregulator research program for respiratory tissue and age-related lung decline. No independently-verified specific study was confirmed for this compound in this research pass — flagging as an open item rather than asserting an unverified claim.
What's the actual idea behind this and the other '-gen' peptides?+
Same core concept across all of them: a very short peptide (2-4 amino acids) designed to target the gene-regulation machinery of one specific organ, on the theory every organ produces its own peptides to stay youthful, and supplementing them can restore that function with age. Bronchogen specifically targets lung and respiratory tissue.
How is this actually used?+
Differently from typical daily peptide dosing — usually run as a short course, around 10-20 days, repeated once or twice a year.
Looking for something specific, or placing a wholesale order? Send us a DM or email.